Evidence map›Paper›PMID 42643958›Full record

ReviewFrontiers in immunology2026

Ferroptosis regulatory networks and precision interventions in autoimmune hepatitis: comparison with cholestatic diseases.

Wenhui Zeng, Jiabing Wang, Yan Xu, Shuzhou Wu, Cixiang Chen, Shanrong Zhang, Bingli Hu, Junsong Ye

Abstract readReviewComparative Study
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenhui ZengSubcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Jiabing WangSubcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Yan XuSubcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Shuzhou WuSubcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Cixiang ChenFirst Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Shanrong ZhangFirst Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Bingli HuSchool of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi, China.
Junsong YeSubcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation, characterized by disruption of iron homeostasis, imbalance in the antioxidant system, and accumulation of lipid peroxides. Its core execution machinery is highly conserved across tissues, whereas disease-specific upstream nodes dictate pathway activation and progression in different pathological contexts. In autoimmune hepatitis (AIH), ferroptosis is governed by a "bidirectional imbalance" between enhanced pro-death signals and compromised anti-death protective mechanisms, further modulated by endocrine and metabolic factors. This imbalance collectively lowers the ferroptosis threshold in hepatocytes, amplifying their susceptibility to ferroptotic cell death. Although hepatocyte ferroptosis has been observed in experimental cholestasis models, these models do not directly represent the pathological process of primary biliary cholangitis (PBC). In PBC patients, recent studies have identified ferroptosis signals in monocyte-derived macrophages, but ferroptosis in biliary epithelial cells remains unconfirmed. In primary sclerosing cholangitis (PSC), despite elevated oxidative stress markers, the absence of core ferroptosis executioner molecules precludes any definitive link to ferroptosis. This review comprehensively summarizes the ferroptosis regulatory network and its disease-specific manifestations across autoimmune liver diseases, with a focus on AIH-specific nodes as potential precision intervention targets. We also propose a phase-based therapeutic framework and discuss safety considerations, as well as key challenges for clinical translation.

Indexed as

CholestasisFerroptosisHepatitis, AutoimmuneAnimalsHepatocytesHumansIronLipid PeroxidationLiver Cirrhosis, BiliaryIronautoimmune diseasesferroptosisliver diseasespathogenesistherapeutic strategies

Identifiers

PMID42643958
PMCPMC13504418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.